scholarly journals In silico directed mutagenesis identifies the CD 81/claudin‐1 hepatitis C virus receptor interface

2012 ◽  
Vol 14 (12) ◽  
pp. 1892-1903 ◽  
Author(s):  
Christopher Davis ◽  
Helen J. Harris ◽  
Ke Hu ◽  
Heidi E. Drummer ◽  
Jane A. McKeating ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
In Silico ◽  
Directed Mutagenesis ◽  
Virus Receptor ◽  
Receptor Interface

scholarly journals Molecular Characterization of Hepatitis C Virus for Developed Antiviral Agents Resistance Mutations and New Insights into in-silico Prediction Studies

2020 ◽  
Vol Volume 13 ◽  
pp. 4235-4248
Author(s):  
Mohamed M Adel El-Sokkary ◽  
Lizaveta Gotina ◽  
Mohammad M. Al-Sanea ◽  
Ae Nim Pae ◽  
Rehab Mohammed Elbargisy
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Molecular Characterization ◽  
In Silico ◽  
Antiviral Agents ◽  
In Silico Prediction ◽  
Resistance Mutations

scholarly journals Anti Hepatitis C virus drugs show potential drug repositioning for SARS CoV-2 main protease: an in silico study

2020 ◽  
Author(s):  
Arthikasree Anandamurthy ◽  
Roslin Elsa Varughese ◽  
Saranya Sivaraj ◽  
Gayathri Dasararaju
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
In Silico ◽  
Drug Repositioning ◽  
Drug Repurposing ◽  
Docking Study ◽  
Binding Potential ◽  
Molecular Docking Study ◽  
Main Protease ◽  
Potent Drug

Abstract Developing effective and safe vaccines/drugs against SARS CoV-2 may take some time. The urgency of the outbreak has led to the usage of broad spectrum of existing anti-viral drugs, across the globe. Among the existing anti-viral drugs, there is still a challenge in identifying the potent drug or the combination of the drugs for the better treatment and faster recovery of the patients. In silico molecular docking study aids in the process of drug repurposing and we aimed to identify the binding potential of some of the existing anti-viral drugs and their interactions at the active site of SARS CoV-2 main protease. Results from our study revealed that the drugs Simeprevir, Elbasvir, Paritaprevir, Beclabuvir, Dasabuvir, Teleprevir, Velpatasvir, Ombitasvir, Ledipasvir, Boceprevir, Asunapervir, Declatasvir, Sofusbuvir which are used in the treatment of Hepatitis C virus infection may act as potent inhibitors for SARS CoV-2 main protease.

Polytope DNA Vaccine Development Against Hepatitis C Virus: A Streamlined Approach from In Silico Design to In Vitro and Primary In Vivo Analyses in BALB/c Mice

2009 ◽  
Vol 16 (7) ◽  
pp. 842-850 ◽  
Author(s):  
Arash Memarnejadian ◽  
Farzin Roohvand ◽  
Arash Arashkia ◽  
Sima Rafati ◽  
Mohammad Shokrgozar
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Dna Vaccine ◽  
In Silico ◽  
Vaccine Development ◽  
In Silico Design
Sign in / Sign up

Export Citation Format

Share Document